Stephen N. Rosenfield
No más puestos en curso
Historial de carrera de Stephen N. Rosenfield
Antiguos cargos conocidos de Stephen N. Rosenfield.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Consejero General | 01/07/2004 | 01/06/2009 |
| Secretario Corporativo | 01/07/2004 | 01/06/2009 | |
| INTERMUNE INC | Consejero General | 01/02/2000 | 01/05/2004 |
| Secretario Corporativo | 01/02/2000 | 01/05/2004 | |
Cooley Godward LLP
 Cooley Godward LLP Miscellaneous Commercial ServicesCommercial Services Cooley Goodword LLP is the law firm specializes in providing services to both new and established information technology and life sciences companies. Cooley also provides counsel in areas of business law that include trade regulation, employment and labor, investment banking issues, securities litigation, IPOs, mergers and acquisitions, patent enforcement and venture capital funding. It is located in Palo Alto, CA. | Corporate Officer/Principal | 01/02/1996 | 01/03/2000 |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Consejero General | 01/03/2000 | 01/03/2000 |
| Corporate Officer/Principal | - | - | |
Topica Pharmaceuticals, Inc.
 Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Consejero General | - | - |
| Secretario Corporativo | - | - | |
| GERON CORPORATION | Consejero General | 01/10/2011 | - |
| Secretario Corporativo | 01/10/2011 | - |
Formación de Stephen N. Rosenfield.
| Hofstra University | Undergraduate Degree |
| Northeastern University School of Law | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 9 |
Operativa
| General Counsel | 5 |
| Corporate Secretary | 4 |
| Corporate Officer/Principal | 2 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GERON CORPORATION | Health Technology |
| Empresas privadas | 5 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Cooley Godward LLP
Cooley Godward LLP Miscellaneous Commercial ServicesCommercial Services Cooley Goodword LLP is the law firm specializes in providing services to both new and established information technology and life sciences companies. Cooley also provides counsel in areas of business law that include trade regulation, employment and labor, investment banking issues, securities litigation, IPOs, mergers and acquisitions, patent enforcement and venture capital funding. It is located in Palo Alto, CA. | Commercial Services |
Topica Pharmaceuticals, Inc.
Topica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topica Pharmaceuticals, Inc. develops treatment for onychomycosis, or fungal infections of the nail and nail bed. Its prodycte, Luliconazole, a topical antifungal a topical antifungal agent used to tinea pedis. The company was founded in 2004 and is headquartered Los Altos, CA. | Health Technology |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
